Integrating CAR-T cell therapy into the management of DLBCL: what we are learning

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

“…Chimeric antigen receptor-modified T-cell (CAR-T) is a clinical and technological revolution ( 1 , 2 ). The more advanced developments that led to the commercialization of the first products, have identified as a target the molecule CD19, expressed in all leukemia acute lymphoblastic leukemia (ALL) ( 3 ) and in Non-Hodgkin Lymphoma (NHL) ( 4 ), such as diffuse (D) large B-cell lymphoma (LBCL) ( 5 ), follicular lymphoma (FL) ( 6 ), mantle-cel lymphoma (MCL) ( 7 ) and the molecule B-cell maturation antigen (BCMA), expresses in multiple myeloma (MM) ( 8 , 9 ). This approach has opened a new page in medicine because we have moved from the drug, understood as an active ingredient packaged and ready to be taken, to a highly personalized therapy.…”